Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Head and Neck Cancer
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1443123

Effect of the gut microbiome and inflammation-related proteins on oral leukoplakia: a Mendelian randomization study and mediation analysis

Provisionally accepted
Junlong Da Junlong Da 1Yinting Ren Yinting Ren 2Shiwei Liu Shiwei Liu 1*Nanyan Wang Nanyan Wang 1*Lei Wang Lei Wang 1*Zhifeng Fu Zhifeng Fu 1*Yongtang Liang Yongtang Liang 1*Yu Pan Yu Pan 1*Jin Li Jin Li 1*Jufeng Chen Jufeng Chen 1*
  • 1 First People's Hospital of Foshan, Foshan, China
  • 2 Department of Stomatology, Foshan Hospital of Traditional Chinese Medicine, Foshan, China

The final, formatted version of the article will be published soon.

    Background: Oral leukoplakia (OL) is the most common potentially malignant disease of the oral cavity. In recent years, studies have identified a correlation between the gut microbiota (GM) and oral cancer, in addition, inflammation-related proteins have been reported to play an important role in the development of OL. However, the causal relationship between gut microbiota and OL, as well as whether cytokines play a mediating role, remain unclear.In this Mendelian randomization (MR) study, the genome-wide association studies (GWAS) (n=18340) of the MiBioGen consortium microbiome was used as exposure data. Genetic variation data related to OL were extracted from the Finngen R9 project (513 cases of OL and 411668 controls). The 91 inflammation-related proteins obtained in the literature serve as potential mediators. Two-sample Mendelian randomization analysis was applied to infer causality using Inverse Variance Weighted (IVW), MR Egger, weighted media, simple mode and weighted mode method. Subsequently, sensitivity analysis was conducted to ensure the robustness of the MR results. In addition, we conducted reverse MR analysis to alleviate reverse causality. Finally, we used mediation analysis to determine the pathway mediated by inflammation-related proteins from the gut microbiota to OL.The five bacterial taxa in the gut microbiota indicate a potential causal relationship with the development of OL. Notably, family Clostridiaceae1 was negatively correlated with the risk of OL development, while genus Dorea, genus Ruminococcus1, genus Senegalimasilia and genus Veillonella were positively associated with the risk of OL development. In addition, this study identified a potential causal relationship between interleukin-10 receptor subunit alpha (IL-10RA), interleukin-18 receptor 1(IL18-R1) and the occurrence of OL. In addition, intermediary analysis indicates that IL18-R1 mediated the pathway between the gut microbiota genus Senegalimasilia and OL.Conclusions: In summary, our research emphasize the complex relationship between gut microbiota, inflammation-related proteins and OL. The identified associations and mediating effects provide new insights into potential therapeutic approaches for targeting the gut microbiota in the management of OL, and contribute to its prevention, diagnosis and treatment.

    Keywords: Gut Microbiota, Oral leukoplakia, inflammation-related proteins, Mendelian randomization, Mediation analysis

    Received: 03 Jun 2024; Accepted: 02 Sep 2024.

    Copyright: © 2024 Da, Ren, Liu, Wang, Wang, Fu, Liang, Pan, Li and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Shiwei Liu, First People's Hospital of Foshan, Foshan, China
    Nanyan Wang, First People's Hospital of Foshan, Foshan, China
    Lei Wang, First People's Hospital of Foshan, Foshan, China
    Zhifeng Fu, First People's Hospital of Foshan, Foshan, China
    Yongtang Liang, First People's Hospital of Foshan, Foshan, China
    Yu Pan, First People's Hospital of Foshan, Foshan, China
    Jin Li, First People's Hospital of Foshan, Foshan, China
    Jufeng Chen, First People's Hospital of Foshan, Foshan, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.